Incidence and predictors of diabetic kidney disease among type 2 diabetes mellitus adult patients in Ethiopia: a systematic review and meta-analysis | BMC Endocrine Disorders
Alfred K, Changchang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1–87. https://doi.org/10.1016/j.kint.2020.11.003.
Google Scholar
International Diabetes Federation, Diabetes Atlas IDF. International Diabetes Federation, Brussels, Belgium, 10th edition, 2021, https://www.diabetesatlas.org
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021. Results. Institute for Health Metrics and Evaluation. 2024 (https://vizhub.healthdata.org/gbd-results/).
Hussain S, Jamali MC, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: an overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Global Health. 2021;9:2–6. https://doi.org/10.1016/j.cegh.2020.05.016.
Google Scholar
Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metabolism. 2020;22:3–15. https://doi.org/10.1111/dom.14007.
Google Scholar
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies. 2019:3–15. https://doi.org/10.1007/978-981-13-8871-2_1
Fenta ET, Eshetu HB, Kebede N, Bogale EK, Zewdie A, Kassie TD, Anagaw TF, Mazengia EM, Gelaw SS. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):245. https://doi.org/10.1186/s13098-023-01202-x.
Google Scholar
Gerber C et al. Incidence and progression of chronic kidney disease in black and white individuals with type 2 diabetes. Clinical Journal of the American Society of Nephrology, 2018. 13(6): pp. 884–892. PMID: 29798889.
Gonza´lez-Pe´rez A, et al. Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK: A cohort study using primary care data from the united Kingdom. Prim Care Diabetes. 2020;14(4):381–7. PMID: 31791904.
Google Scholar
Koye DN et al. Trends in the incidence of ESKD in people with type 1 and type 2 diabetes in Australia, 2002–2013. American Journal of Kidney Diseases, 2019. 73(3): pp. 300–308. PMID: 30579709.
Tsai MH, Hsu CY, Lin MY, Yen MF, Chen HH, Chiu YH, Hwang SJ. Incidence, prevalence, and duration of chronic kidney disease in taiwan: results from a community-based screening program of 106,094 individuals. Nephron. 2018;140(3):175–84. PMID: 30138926.
Google Scholar
Xie D, Ma T, Cui H, Li J, Zhang A, Sheng Z, Xie Y. Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20–59 years, 1990–2019. Sci Rep. 2023;13(1):20234. https://doi.org/10.1038/s41598-023-47091-y.
Google Scholar
Shiferaw WS, Akalu TY, Aynalem YA. Chronic kidney disease among diabetes patients in ethiopia: a systematic review and meta-analysis. Int J Nephrol. 2020;2020(1):8890331. https://doi.org/10.1155/2020/8890331.
Google Scholar
Moazzeni SS, Arani RH, Hasheminia M, Tohidi M, Azizi F, Hadaegh F. High incidence of chronic kidney disease among Iranian diabetic adults: using CKD-EPI and MDRD equations for estimated glomerular filtration rate. Diabetes Metabolism J. 2021;45(5):684–97. https://doi.org/10.4093/dmj.2020.0109.
Google Scholar
International Diabetes Federation, Diabetes Atlas IDF. International Diabetes Federation, Brussels, Belgium, 9th edition, 2019.
Luyckx VA, Al-Aly Z, Bello AK, Bellorin-Font E, Carlini RG, Fabian J, Garcia-Garcia G, Iyengar A, Sekkarie M, Van Biesen W, Ulasi I. Sustainable development goals relevant to kidney health: an update on progress. Nat Rev Nephrol. 2021;17(1):15–32.
Google Scholar
Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, Donner JA, Caskey FJ, Cho Y, Davids MR, Davison SN. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Global Health. 2024;12(3):e382–95. https://www.theisn.org/wpcontent/uploads/media/ISN%20Atlas_2023%20Digital_REV_2023_10_03.pdf.
Google Scholar
Fernandez RM. SDG3 good health and well-being: integration and connection with other SDGs. Good health and well-being. 2020:629– 36.
Ethiopia Federal Minister of Health. Standard Treatment Guideline for General Hospital, fourth Edition, Addis Ababa 2021.
Geletu AH, Teferra AS, Sisay MM, Teshome DF. Incidence and predictors of chronic kidney diseases among type 2 diabetes mellitus patients at st. Paul’s hospital, addis ababa, Ethiopia. BMC Res Notes. 2018;11:1–6. https://doi.org/10.1186/s13104-018-3618-9.
Google Scholar
Tamru K, Aga F, Berhanie E, Aynalem YA, Shiferaw WS. Incidence of diabetic kidney disease in patients with type 2 diabetes mellitus at a tertiary healthcare setting in Ethiopia. Diabetes Metabolic Syndrome: Clin Res Reviews. 2020;14(5):1077–83. https://doi.org/10.1016/j.dsx.2020.06.028.
Google Scholar
Kebede SA, Tusa BS, Weldesenbet AB, Tessema ZT, Ayele TA. Incidence of diabetic kidney disease and its predictors among type 2 diabetes mellitus patients at university of Gondar comprehensive specialized hospital, Northwest Ethiopia. J Nutr Metabolism. 2021;2021(1):6757916. https://doi.org/10.1155/2021/6757916.
Google Scholar
Debele GR, Hajure M, Wolde HF, Yenit MK. Incidence and predictors of chronic kidney disease among diabetes mellitus patients: a retrospective follow-up study at a tertiary health-care setting of ethiopia. Diabetes, metabolic syndrome and obesity. 2021 Oct 28:4381–90. https://doi.org/10.2147/DMSO.S335572
Ahmed MA, Ferede YM, Takele WW. Incidence and predictors of chronic kidney disease in type-II diabetes mellitus patients attending at the Amhara region referral hospitals, ethiopia: a follow-up study. PLoS ONE. 2022;17(1):e0263138. https://doi.org/10.1371/journal.pone.0263138.
Google Scholar
Tekalign T, Guta MT, Awoke N, Chichiabellu TY, Meskele M, Anteneh G, Tura TS, Workie SB. Time to diabetic kidney disease and its predictors among diabetic patients treated in Wolaita and Dawuro zone hospitals, ethiopia: a retrospective cohort study. Int J Nephrol Renovascular Disease 2023 Dec 31:163–72. https://doi.org/10.2147/IJNRD.S396574
Merid F, Getahun F, Esubalew H, Gezahegn T. Incidence and predictors of diabetic kidney disease among type 2 diabetes mellitus patients, Southern Ethiopia. J Nutr Metabolism. 2024;2024(1):6976870. https://doi.org/10.1155/2024/6976870.
Google Scholar
Cheru A, Edessa D, Regassa LD, Gobena T. Incidence and predictors of chronic kidney disease among patients with diabetes treated at governmental hospitals of Harari region, Eastern ethiopia, 2022. Front Public Health. 2024;11:1290554. https://doi.org/10.3389/fpubh.2023.1290554.
Google Scholar
Munn Z, Stone J, Aromataris E, Klugar M, Sears K, Leonardi-Bee J, Barker T. Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evid Synthesis. 2022. https://doi.org/10.11124/jbies-22-00224.
Google Scholar
Glasgow M, Edlin R, Harding J. Comparison of risk-of-bias assessment approaches for selection of studies reporting prevalence for economic analyses. BMJ Open. 2020;10. https://doi.org/10.1136/bmjopen-2020-037324.
Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15:1–7. https://doi.org/10.1186/s12874-015-0091-1.
Google Scholar
Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16(4):195–203. https://doi.org/10.1097/XEB.0000000000000141.
Google Scholar
Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dialysis. 2022;2(3):433–42. https://doi.org/10.3390/kidneydial2030038.
Google Scholar
Ray N, Reddy PH. Structural and physiological changes of the kidney with age and its impact on chronic conditions and COVID-19. Ageing Res Rev. 2023;88:101932. https://doi.org/10.1016/j.arr.2023.101932.
Google Scholar
Shuvo SD, Hossen MT, Riazuddin M, Hossain MS, Mazumdar S, Parvin R, Elahi MT. Prevalence of comorbidities and its associated factors among type-2 diabetes patients: a hospital-based study in Jashore district, Bangladesh. BMJ Open. 2023;13(9):e076261. https://doi.org/10.1136/bmjopen-2023-076261.
Google Scholar
Li J, Green M, Kearns B, et al. Patterns of Multimorbidity and their association with health outcomes within yorkshire, england: baseline results from the Yorkshire health study. BMC Public Health. 2016;16:649. https://doi.org/10.1186/s12889-016-3335-z.
Google Scholar
Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. https://doi.org/10.1186/s12933-018-0728-6.
Google Scholar
Yokomichi H, Nagai A, Hirata M, et al. Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer, and smoking in patients with type 2 diabetes: biobank Japan cohort. J Epidemiol. 2017;27:S98–106. https://doi.org/10.1016/j.je.2016.12.012.
Google Scholar
Bernabe-Ortiz A, Borjas-Cavero DB, Páucar-Alfaro JD, et al. Multimorbidity patterns among people with type 2 diabetes mellitus: findings from Lima. Peru IJERPH. 2022;19:9333. https://doi.org/10.3390/ijerph19159333.
Google Scholar
Lopes de Faria JB, Silva KC, Lopes de Faria JM. The contribution of hypertension to diabetic kidney disease and retinopathy: the role of inflammation and oxidative stress. Hypertens Res. 2011;34(4):413–22. https://doi.org/10.1038/hr.2010.263.
Google Scholar
Wagnew F, Eshetie S, Kibret GD, Zegeye A, Dessie G, Mulugeta H, Alemu A. Diabetic kidney disease and hypertension in diabetes patients of sub-Saharan countries: a systematic review and meta-analysis. BMC Res Notes. 2018;11:1–7. https://doi.org/10.1186/s13104-018-3670-5.
Google Scholar
Wang M, Li J, Li Y, Yao S, Zhao M, Wang C, Wu S, Xue H. The effects of hypertension and diabetes on new-onset chronic kidney disease: a prospective cohort study. J Clin Hypertens. 2020;22(1):39–46. https://doi.org/10.1111/jch.13768.
Google Scholar
Alsaadon H, Afroz A, Karim A, Habib SH, Alramadan MJ, Billah B, Shetty AN. Hypertension and its related factors among patients with type 2 diabetes mellitus–a multi-hospital study in Bangladesh. BMC Public Health. 2022;22(1):198. https://doi.org/10.1186/s12889-022-12509-1.
Google Scholar
Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74. https://doi.org/10.1186/s12933-022-01516-6.
Google Scholar
Sattar N, Presslie C, Rutter MK, McGuire DK. Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary Understanding with greater emphasis on excess adiposity. Diabetes Care. 2024;47(4):531–43. https://doi.org/10.2337/dci23-0041.
Google Scholar
Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1· 9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13. https://doi.org/10.1016/S2213-8587(14)70219-0.
Google Scholar
Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023;12(22):6984. https://doi.org/10.3390/jcm12226984.
Google Scholar
Annose RT, Asefa H, Gezahagn Y, Abebe G, Zewde TH. Determinants of cardiovascular disease among type 2 diabetic patients attending diabetic follow-up clinic in Arba minch general hospital, Southern ethiopia: an unmatched case-control study. Annals Med Surg. 2024;86(5):2467–73. https://doi.org/10.1097/MS9.0000000000001951.
Google Scholar
Pálsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):273–80. https://doi.org/10.1053/j.ackd.2014.03.003.
Google Scholar
Busch M. Cardiovascular disease in diabetic nephropathy: pathophysiology and treatment. Diabetes and kidney disease. Jan. 2013;10:83–100. https://doi.org/10.1002/9781118494073.ch7.
Google Scholar
Lui DT, Li L, Liu X, Xiong X, Tang EH, Lee CH, Woo YC, Lang BH, Wong CK, Tan KC. The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study. BMC Med. 2024;22(1):586. https://doi.org/10.1186/s12916-024-03810-4.
Google Scholar
Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, Celermajer DS, Beulens JW, Stolk RP, Glasziou P, Ng MK. Low HDL cholesterol and the risk of diabetic kidney disease and retinopathy: results of the ADVANCE study. Diabetes Care. 2012;35(11):2201–6. https://doi.org/10.2337/dc12-0306.
Google Scholar
Palazhy S, Viswanathan V. Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metabolism J. 2017;41(2):128. https://doi.org/10.4093/dmj.2017.41.2.128.
Google Scholar
Yan Z, Xu Y, Li K, Liu L. Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus: dual evidence from NHANES database and Mendelian randomization analysis. Front Endocrinol. 2024;15:1272314. https://doi.org/10.3389/fendo.2024.1272314.
Google Scholar
Kunutsor SK, Kieneker LM, Bakker SJL, James RW, Dullaart RPF. Incident type 2 diabetes is associated with hdl, but not with its anti-oxidant constituent – paraoxonase-1: the prospective cohort prevend study. Metabolism. 2017;73:43–515. https://doi.org/10.1016/j.metabol.2017.05.004.
Google Scholar
Thacker SG, Zarzour A, Chen Y, Alcicek MS, Freeman LA, Sviridov DO, et al. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology. 2016;149:306–195. https://doi.org/10.1111/imm.12638.
Google Scholar
Asztalos BF, Hauser TH, Goldfine AB, Welty FK, Horvath KV, Schaefer EJ. The role of hdl- and non-hdl-related parameters in cell-cholesterol efflux capacity. Atherosclerosis. 2022;345:1–65. https://doi.org/10.1016/j.atherosclerosis.2022.02.012.
Google Scholar
Jia C, Anderson JLC, Gruppen EG, Lei Y, Bakker SJL, Dullaart RPF, et al. High-density lipoprotein anti-inflammatory capacity and incident cardiovascular events. Circulation. 2021;143:1935–455. https://doi.org/10.1161/CIRCULATIONAHA.120.050808.
Google Scholar
Adorni MP, Ronda N, Bernini F, Zimetti F. High density lipoprotein cholesterol efflux capacity and atherosclerosis in cardiovascular disease: pathophysiological aspects and Pharmacological perspectives. Cells. 2021;10:574. https://doi.org/10.3390/cells10030574.
Google Scholar
Hwang YC, Ahn HY, Park SW, Park CY. Association of hdl-c and Apolipoprotein a-i with the risk of type 2 diabetes in subjects with impaired fasting glucose. Eur J Endocrinol. 2014;171:137–425. https://doi.org/10.1530/EJE-14-0195.
Google Scholar
link
